Clinical Trials | December 07, 2025
Bayer launches phase III trial testing Mirena for uterine condition with no treatments
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Importantly, the combination of giredestrant and everolimus was well tolerated
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Subscribe To Our Newsletter & Stay Updated
